We are live on ! Find out more
APRE icon

Aprea Therapeutics
APRE

66 hedge funds and large institutions have $50.3M invested in Aprea Therapeutics in 2020 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 16 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 16

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

3% more funds holding

Funds holding: 64 → 66 (+2)

1.54% less ownership

Funds ownership: 3.97% → 2.43% (-1.5%)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

88% less capital invested

Capital invested by funds: $404M → $50.3M (-$354M)

Holders
66
Holders Change
+2
Holders Change %
+3.13%
% of All Funds
1.17%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
15
Increased
25
Reduced
16
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$9.63M
2
BlackRock
BlackRock
New York
+$8.09M
3
Artisan Partners
Artisan Partners
Wisconsin
+$5.39M
4
CCM
CAAS Capital Management
New York
+$4.38M
5
Two Sigma Investments
Two Sigma Investments
New York
+$3.78M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$45.1M
2
CCM
Consonance Capital Management
New York
-$35.1M
3
RG
Redmile Group
California
-$23.8M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$20.5M
5
5VM
5AM Venture Management
California
-$19.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Skandinaviska Enskilda Banken (SEB)
51
Skandinaviska Enskilda Banken (SEB)
Sweden
$11K – – –
SO
52
STRS Ohio
Ohio
$8K – – –
SWM
53
Sugarloaf Wealth Management
Georgia
$7K +$35.7K +75 New
Legal & General Group
54
Legal & General Group
United Kingdom
$6K -$476 -1 -2%
Canada Life
55
Canada Life
Manitoba, Canada
$6K – – –
Bank of Montreal
56
Bank of Montreal
Ontario, Canada
$6K +$18.1K +38 +224%
AIP
57
Ameritas Investment Partners
Nebraska
$3K – – –
UBS Group
58
UBS Group
Switzerland
$3K +$15.7K +33 +1,650%
Fidelity International
59
Fidelity International
Bermuda
$2K +$4.28K +9 +60%
PCM
60
Penserra Capital Management
California
$2K +$11.4K +24 New
KTC
61
Kistler-Tiffany Companies
Pennsylvania
$2K +$11.9K +25 New
Macquarie Group
62
Macquarie Group
Australia
$1K – – –
WEC
63
Winslow Evans & Crocker
Massachusetts
$1K – – –
Walleye Capital
64
Walleye Capital
New York
$496 +$2.4M +5,040 New
AIG
65
American International Group
New York
$21 -$2.85K -6 -3%
CCM
66
Consonance Capital Management
New York
– -$35.1M -72,971 Closed
Janus Henderson Group
67
Janus Henderson Group
United Kingdom
– -$20.5M -42,559 Closed
RSCM
68
Rock Springs Capital Management
Maryland
– -$12.5M -25,915 Closed
KCM
69
Kennedy Capital Management
Missouri
– -$4.51M -9,368 Closed
Point72 Asset Management
70
Point72 Asset Management
Connecticut
– -$3.06M -6,349 Closed
Citadel Advisors
71
Citadel Advisors
Florida
– -$1.78M -3,704 Closed
AI
72
Atom Investors
Texas
– -$843K -1,753 Closed
Goldman Sachs
73
Goldman Sachs
New York
– -$795K -1,653 Closed
SFI
74
Susquehanna Fundamental Investments
Pennsylvania
– -$589K -1,225 Closed
PHP
75
Parkman Healthcare Partners
Connecticut
– -$482K -1,002 Closed
1 2
3
4

APRE Hedge Fund Activity: Q4 2020 in Review

66 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Aprea Therapeutics (APRE) for Q4 2020, worth a combined $50.3M — down 88% from $404M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new APRE positions and 13 closed out — a net gain of 2 holders — while 25 added to existing stakes and 16 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $9.63M. The largest seller was Fidelity Investments, cutting an estimated $45.1M.

  • 66 institutional investors held Aprea Therapeutics (APRE) as of Q4 2020, up from 64 in Q3 2020.
  • Funds reported $50.3M of Aprea Therapeutics stock for Q4 2020, down 88% quarter-over-quarter.
  • 15 funds opened new Aprea Therapeutics positions in Q4 2020 and 13 closed out, a net change of +2 holders.
  • The largest Aprea Therapeutics buyer in Q4 2020 was Morgan Stanley, an estimated $9.63M added.
  • The largest Aprea Therapeutics seller in Q4 2020 was Fidelity Investments, an estimated $45.1M sold.

Based on aggregated 13F filings for Q4 2020.